Stockscreener 앱 받기
0.5342
5.90%
-0.0335
시간 외 거래:
.54
0.0058
+1.09%
전일 마감가:
$0.5677
열려 있는:
$0.62
하루 거래량:
2.00M
Relative Volume:
1.24
시가총액:
$31.41M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.2063
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
-36.01%
1개월 성능:
-31.46%
6개월 성능:
+34.32%
1년 성능:
-13.00%
1일 변동 폭
$0.533
$0.62
1주일 범위
$0.533
$0.835
52주 변동 폭
$0.2601
$1.43
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.5342 | 33.38M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Nigeria
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - Defense World
Can BioAtla Inc. stock reach $100 price targetGap Up & Safe Swing Trade Setup Alerts - Улправда
Aug Drivers: Why retail investors pile into BioAtla Inc. stockInsider Selling & Weekly Watchlist of Top Performers - Улправда
How BioAtla Inc. stock performs in rising dollar environmentWeekly Trade Analysis & Technical Confirmation Trade Alerts - Улправда
Why retail investors pile into BioAtla Inc. stockTrade Volume Report & Technical Pattern Alert System - Улправда
How rising interest rates impact BioAtla Inc. stock2025 Bull vs Bear & Weekly Momentum Stock Picks - DonanımHaber
Can BioAtla Inc. stock rebound after recent weakness2025 Analyst Calls & Verified Stock Trade Ideas - Улправда
Can BioAtla Inc. stock resist market sell offsEarnings Overview Report & Daily Entry Point Alerts - Улправда
BioAtla Earnings Notes - Trefis
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
BioAtla (NASDAQ: BCAB) seeks approval for stock issuance and reverse split - Stock Titan
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
CFO Waldron Surrenders 2,371 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Officer Vasquez Surrenders 1,566 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
BioAtla, Inc. (BCAB) -11.3% in Intraday Trading: What’s Driving the Move? - Stocks Telegraph
BioAtla Inc. (BCAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The growth track for BioAtla Inc (BCAB) has changed recently - setenews.com
[PRE 14A] BioAtla, Inc. Preliminary Proxy Statement - Stock Titan
BioAtla Reports Q3 2025 Financial Results and Progress - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Form 424B5 BioAtla, Inc. - StreetInsider
[424B5] BioAtla, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
[8-K] BioAtla, Inc. Reports Material Event | BCAB SEC FilingForm 8-K - Stock Titan
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):